Clinical Trials Directory

Trials / Conditions / Immune-Related Adverse Events

Immune-Related Adverse Events

12 registered clinical trials studyying Immune-Related Adverse Events — 9 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingStudy on Biomarkers of Immune-Related Adverse Events
NCT07527585
Huazhong University of Science and Technology—
RecruitingManagement of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids
NCT07167251
University Hospital, Basel, Switzerland—
RecruitingEvaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepos
NCT06789601
Brigham and Women's HospitalPhase 1 / Phase 2
RecruitingAdebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
NCT07430579
The Second Hospital of Shandong UniversityN/A
RecruitingInterferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimm
NCT07249060
Hospital Universitario Araba—
RecruitingImmune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
NCT07453342
Peking Union Medical College Hospital—
CompletedECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
NCT05414552
University of Freiburg—
RecruitingMulti-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinica
NCT04840355
Guohui Li—
Active Not RecruitingStudy of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
NCT04375228
Columbia UniversityPhase 2
UnknownPD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
NCT04115410
Sungkyunkwan University—
RecruitingA Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade
NCT04807127
Universitaire Ziekenhuizen KU Leuven—
RecruitingLongitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpo
NCT07357636
Shantou University Medical College—